TECHNOLOGY LICENSING OFFICE
4301 West Markham Street, #831
Little Rock, AR 72205
501.686.6696
email: nmgray@uams.edu

BV 2017-17 - *Compositions and Methods for Detecting Sessile Serrated Adenomas/Polyps*

APPLICATION:

Platform independent assay to distinguish between sessile serrated adenomas and hyperplastic polyps

KEY BENEFITS:

- Accurate diagnosis of colon cancer and polyps
- Allows appropriate treatment decisions
- Economical

MARKET SUMMARY:

Colon cancer is the second largest cause of cancer-related deaths in the United states. Colonic neoplasms originate primarily from colon polyps and develop partially overlapping but mechanistically distinct pathways that have been designated as the adenomatous and serrated pathways. Evidence indicates that the majority of other colon adenocarcinomas, possibly 20-30%, arise from a subset of serrated polyps, designated sessile serrated adenomas/polyps (SSA/Ps), which were previously classified as hyperplastic polyps (HPs) and thought to have little or no tumorigenic potential.

SSA/Ps have been distinguished from HPs on the basis of their endoscopic appearance (larger, flat and hypermucinous) and histologic characteristics (dilatated crypts, horizontal crypts, and boot shaped deformities). Because SSA/Ps and HPs may have overlapping and similar features, including serrated crypt architecture, misclassification is common. Because SSA/Ps account for 20-30% of colon cancers and HPs have little risk of progressing to cancer, misclassification results in inadequate patient follow up or unnecessary cancer screening.

TECHNICAL SUMMARY:

University inventors have identified a method of distinguishing between SSA/Ps and HPs at a molecular level. In this way, subjective analysis of the appearance of the neoplasms is removed from the process, and misclassifications are greatly reduced. The technology also provides for a predictive tool to accurately determine the risk that a colorectal polyp will develop into a cancer.

BV 2017-17 - *Compositions and Methods for Detecting Sessile Serrated Adenomas/Polyps*

Continued

DEVELOPMENTAL STAGE:

Validated with human patient samples

PATENT INFORMATION AND CONTACT:

App Type: PCT
Country: US
Serial No.: PCT/US2018/020517
Patent No.:
File Date: 03/01/2018
Issue Date:
Inventor(s): Curt Hagedorn, Yassir Rahmatallah, Galina Glazko
Tech ID: 1717
Contact: Joe Underwood, Associate Director – Licensing, junderwood@uams.edu